Abstract
Background
Most intragastric balloons have 6-month approval. We report results with the Spatz Adjustable Balloon: approved for 12 months and adjustable.
Methods
Seventy-three patients (mean: age 45.5; weight 114.5 kg; BMI 36.6 kg/m2) scheduled for 1-year implantation with Spatz balloon (mean volume 417 ml saline). Adjustments performed for early intolerance and weight loss plateau.
Results
Three patients failed insertion. There were 21 early removals (4 intolerant refusing adjustment; 3 deflations; 14 satisfied patients) leaving 49 patients at 12 months. Results of 70 patients (49 patients at 12 months and 21 patients at <12 months) were a mean 21.6 kg weight loss; 19 % weight loss; and 45.7 % EWL (excess weight loss). Ten intolerant patients were adjusted and lost additional mean 13.2 kg. Fifty-one patients with weight loss plateau scheduled for adjustment: adjustments failed in 6 and non-response in 7. The adjusted 38 patients lost an additional mean 9.4 kg and at extraction had mean 40.9 % EWL with 18.7 % weight loss. Three catheter impactions required surgical extraction, and three deflated balloons didn’t migrate beyond stomach.
Conclusions
The Spatz balloon is an effective procedure without mortality; however, it carries a risk of catheter impaction necessitating surgical extraction (4.1 %). The failure rate—4.1 %; intolerance without ability to adjust balloon—5.5 %; major complications occurred in 3 (4.1 %); minor (balloon deflations) in 3 (4.1 %), and 2 asymptomatic gastric ulcers at extraction (2.7 %). The longer implantation period and adjustment option combine to produce greater weight loss, albeit <10 % weight loss beyond the pre-adjustment weight loss.
Similar content being viewed by others
References
Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4.
Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.
Bonazzi P, Petrelli MD, Lorenzini I, et al. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci. 2005;9(5 Suppl 1):15–21.
Mion F, Napoléon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in nonmorbid obese patients. Obes Surg. 2005;15(4):510–6.
Evans JD, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001;88(9):1245–8.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14(7):991–8.
Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomized, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006;30(1):129–33.
Doldi SB, Micheletto G, Perrini MN, et al. IGB; another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51(55):294–7.
Roman S, Napoleon B, Mion F, et al. IGB for non-morbid obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539–44.
Doldi SB, Micheletto G, Di Prisco F, et al. IGB in obese patients. Obes Surg. 2000;10(6):578–81.
Al-Momen A, El-Mogy I. IGB for obesity; a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15(1):101–5.
Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients 1 year after the IGB has been removed? Obes Surg. 2005;15(6):864–70.
Melissas J, Mouzas J, Filis D, et al. The IGB—smoothing the path to bariatric surgery. Obes Surg. 2006;16(7):897–902.
Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by IGB in super obese patients treated with laparoscopic gastric banding: a case control study. Obes Surg. 2004;14(5):671–6.
Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with IGB in association with diet. Obes Surg. 2002;12(4):583–7.
Totte E, Hendrickx L, Pauwels M, et al. Weight reduction by means of an intragastric device; experience with BIB. Obes Surg. 2001;11(4):519–23.
Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011;21(10):1499–507.
Gaggiotti G, Tack J, Garrido Jr AB, et al. Adjustable totally implantable intragastric prosthesis (ATIIP)—Endogast for treatment of morbid obesity: one-year follow-up of a multicenter prospective clinical survey. Obes Surg. 2007;17(7):949–56.
Espinet-Coll E, Nebreda-Durán J, Gómez-Valero J, et al. Current endoscopic techniques in the treatment of obesity. Rev Esp Enferm Dig (Madrid). 2012;104(2):72–87.
NIH Conference. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–61.
Alfalah H, Philippe B, Ghazal F, et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg. 2006;16(2):147–50.
Vandenplas Y, Bollen P, De Langhe K, et al. Intragastric balloons in adolescents with morbid obesity. Eur J Gastroenterol Hepatol. 1999;11(3):243–5.
Al Kahtani K, Khan MQ, Helmy A, et al. Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal Specialist Hospital experience. Obes Surg. 2010;20(9):1219–26.
Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric balloon therapy. Obes Surg. 1999;9:261–4.
Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20(8):1128–32.
Lopez-Nava G, Angel Rubio M, Prados S, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.
Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs. intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.
Genco A, Bruni T, Doldi SB, et al. Bioenterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.
Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.
Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric® Intragastric Balloon (BIB®) as a treatment for obesity: poor results in Asian patients. Singap Med J. 2007;48(3):227–31.
Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow up. Gastrointest Endosc. 2005;61:19–27.
Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80.
Vanden Eynden F, Urbain P. Small intestine gastric balloon impaction treated by laparoscopic surgery. Obes Surg. 2001;11(5):646–8.
Francica G, Giardiello C, Scarano F, et al. Ultrasound diagnosis of IGB complications in obese patients. Radiol Med (Torino). 2004;108(4):380–4.
Kim WY, Kirkpatrick UJ, Moody AP, et al. Large bowel impaction by the BIB necessitating surgical intervention. Ann R Coll Surg Engl. 2000;82(3):202–4.
Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8.
Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon springs, Florida, March 19–21, 1987. Gatrointest Endosc. 1987;33:323–7.
Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon. A prospective study on 100 patients. Obes Surg. 2010;20(11):1096–05.
Genco A, Dellepiane D, Baglio G, et al. Adjustable intragastric balloon vs. non-adjustable intragastric balloon: case control study on complications, tolerance and efficacy. Obes Surg. 2013. doi:10.1007/s 11695-013-0891-5.
Brooks J. One year adjustable intragastric balloons: do they offer more than 2 consecutive non-adjustable 6 month balloons? A response to Genco A, et al. Obes Surg. 2013;23(12):2104–5.
Hodson RM, Zacharoulis D, Goutzamani E, et al. Management of obesity with the new intragastric balloon. Obes Surg. 2001;11:327–9.
Lecumberri E, Krekshi W, Matia P, et al. Effectiveness and safety of air filled balloon Heliosphere Bag in 82 consecutive obese patients. Obes Surg. 2011;21(10):1508–12.
Disclosure
Dr Jeffrey Brooks is a shareholder and serves as CEO of Spatz FGIA, Inc. which manufactures the Spatz device. Dr Srivastava and Dr Mathus-Vliegen have no conflict of interest to report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brooks, J., Srivastava, E.D. & Mathus-Vliegen, E.M.H. One-year Adjustable Intragastric Balloons: Results in 73 Consecutive Patients in the UK. OBES SURG 24, 813–819 (2014). https://doi.org/10.1007/s11695-014-1176-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-014-1176-3